Archives for November 2007

UK Soft Water Eczema Trial

In the very first trial of its kind in the world over 300 families are being recruited to find out if water softeners can help in the treatment of childhood eczema.The independent trial run by clinicians at The University of Nottingham has received funding of nearly £1million from the Department of Health’s National Institute for [...]

30 November 2007 | Dermatology | No Comments

Reducing Inflammation In Damaged Skin Tissue Aided By Exercise

In recent years, researchers at the University of Illinois have uncovered a host of reasons for people to remain physically active as they age, ranging from better brain function to improved immune responses.Now a new U. of I. study points to yet another benefit: a link between moderate exercise and decreased inflammation of damaged skin [...]

29 November 2007 | Dermatology | No Comments

Chilly Winter Weather Causes Skin Woes For Men

Women know that a change in season means a change in skin care regime. But it is important to keep in mind that men have special winter skin care concerns that should not be overlooked. Most people are unaware of how much sun damage they can sustain during the winter, and men especially [...]

29 November 2007 | Dermatology | No Comments

Transport’s Phase 2 Data Show Single Treatment SoloVir™ ETS Significantly Stops Progression Of Cold Sore Episode

Yesterday at the 19th Annual Piper Jaffray Health Care Conference, Dr. Dennis I. Goldberg, President and Chief Executive Officer of Transport Pharmaceuticals, Inc., presented compelling clinical results of a Phase 2 study designed to evaluate the safety and efficacy of the company’s lead drug/device product, the SoloVir™ Electrokinetic Transdermal System (SoloVir™ ETS) for recurrent herpes [...]

29 November 2007 | Dermatology | No Comments

Transport’s Phase 2 Data Show Single Treatment SoloVir(TM) ETS Significantly Stops Progression Of Cold Sore Episode

At the 19th Annual Piper Jaffray Health Care Conference, Dr. Dennis I. Goldberg, President and Chief Executive Officer of Transport Pharmaceuticals, Inc., presented compelling clinical results of a Phase 2 study designed to evaluate the safety and efficacy of the company’s lead drug/device product, the SoloVir(TM) Electrokinetic Transdermal System (SoloVir(TM) ETS) for recurrent herpes [...]

29 November 2007 | Dermatology | No Comments

Results Of The Relieva(R) Clinical Trial In Eczema Treatment Published

The results of the study conducted in the USA. to determine the efficacy and tolerability of Relieva® in adult patients with Atopic Dermatitis (eczema) were just published in the September issue of the American Journal of Therapeutics (14:442-446, 2007). Previous laboratory studies showed that Psorberine®, the active ingredient of Relieva®, a non-corticoid, non- immunosuppressant but [...]

28 November 2007 | Dermatology | No Comments

Infection Outbreaks On Teeth Can Cause ‘Alopecia Areata’ Or Localized Hair Loss

There is a close relationship between infection outbreaks on teeth and the presence of alopecia areata or localized alopecia, a type of hair loss which has an unknown origin. Alopecia areata starts with bald patches on the scalp, and sometimes elsewhere on the body. The disease occurs in males and females of all ages, and [...]

28 November 2007 | Dermatology | No Comments

FDA Extends Comment Period For Proposed Sunscreen Rule

The Food and Drug Administration announced that it will be extending the comment period on the agency’s proposed sunscreen regulation to Dec. 26, 2007. The comment period was set to expire on Nov. 26. Typically, comment periods for Federal rules is 90 days. [click link for full article]
Original post by Dermatology News From Medical News [...]

28 November 2007 | Dermatology | No Comments

Isolagen Modifies Ongoing Clinical Program For Acne Scars

Isolagen(TM), Inc. (Amex: ILE) announced that the Food and Drug Administration (FDA) has provided follow-up on the Phase III program investigating the Isolagen Therapy(TM) for the treatment of moderate to severe acne scars. The FDA reiterated that there are no safety issues that would prevent the initiation of the proposed studies. [click link for [...]

28 November 2007 | Dermatology | No Comments

CSL Behring Reaches Primary Endpoint In Clinical Study Of C1-INH For Treatment Of Hereditary Angioedema

CSL Behring announced today that it has reached the primary endpoint of a Phase III clinical trial of human pasteurized C1-inhibitor (C1-INH) concentrate to treat patients with hereditary angioedema (HAE), a rare genetic disorder that can lead to painful and sometimes life-threatening attacks of edema (swelling) of the face, airway, abdomen, and [...]

27 November 2007 | Dermatology | No Comments

Navigation

News Archives

Sponsors